After taking the helm and pointing South San Francisco-based iPierian in a new direction, CEO Nancy Stagliano today unveiled a $30 million venture round designed to get her crew into the clinic with a lead antibody program, while a separate project is being spun out into a new biotech that she will also direct.
In the latest biotech business formed around a major drugmaker's assets, Atara Biotherapeutics has emerged with early-stage drug candidates against cancer and other serious diseases from biopharma behemoth Amgen.
San Diego-based Elcelyx Therapeutics is jumping out of stealth mode today with news that it has picked up an extended venture round, bringing its total venture backing to $20 million as the fledgling biotech pursues a new formulation of metformin as well as a dietary supplement.
This morning the biotech--which is backed by Google Ventures, Third Rock and Kleiner Perkins--announced that Novartis is expanding on their pact with plans to use the test to properly match patients to most of their Phase I and Phase II cancer trials over the next three years.
Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.
A pair of high-profile venture investors has joined forces to finance a startup sequencing outfit that has some ambitious near-term marketing plans to start selling a test that can help match cancer
Kleiner Perkins Caufield & Byers' Chinese arm has reportedly struck a deal to invest $15 million in a biotech company located in the eastern region of the country. Quoting sources, Reuters said
You can expect to see a considerable amount of scrambling among vaccine makers as swine flu grabs headlines and raises fears of a global pandemic. The Chicago Tribune reported Monday morning that
Mark Levin earned a reputation for a colorful personality with an incredible knack for raising cash as co-founder of Millennium Pharmaceuticals. Two weeks ago, Takeda helped seal Levin's reputation
San Mateo, CA-based Corthera has closed a $23 million third round of venture capital. Caxton Advantage Life Sciences Fund joined A-list life science investors Domain Associates and Kleiner, Perkins,